DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- GeneCentric, a company making precision medicine more precise by bringing gene expression biology to liquid biopsy, today announced that it will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place in San Diego, California from April 17-22. The company will also participate in the Myriad Genetics Spotlight Theater (“Advances in ctDNA Testing towards Biopharma Development & Clinical Dx”) and Discovery Life Sciences Flash Talk during the meeting.
“Our 2026 AACR presentations will showcase the significant progress we’ve made in advancing our ExpressCT™ liquid biopsy technology,” said Michael Milburn, PhD, President and Chief Executive Officer of GeneCentric. “Along with our collaborators, we look forward to presenting new data highlighting how ExpressCT is not tied to a single assay format but is compatible with whole genome sequencing, established gene panels, and our custom-designed GenomicsNext™ hybrid-capture panel. Our data show that fragmentomics can provide prognostic insight, detect established therapeutic markers such as ER and other gene signatures, and demonstrate a path extending liquid biopsy utility beyond mutation profiling.”
Myriad Genetics Spotlight Theater
Date & Time: Sunday, April 19, 3:30 – 4:30pm PT
Location: Theater B
Title: Advances in ctDNA Testing towards Biopharma Development & Clinical Dx
Speaker: Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics
Title: Expanding liquid biopsy utility by inferring gene expression from cfDNA with ExpressCT™ fragmentomics technology
Speaker: Michael Milburn, PhD, President and CEO, GeneCentric
Poster Sessions
Date & Time: Tuesday, April 21, 9:00am – 12:00pm PT
Title: Fragmentomic analysis of cfDNA WGS at regulatory regions generates gene-level expression-like traits for subtype analysis in breast cancer
Abstract Number: 4049
Session Title: Liquid Biopsies: Circulating Nucleic Acids 4
Poster Section: 45 | Poster Board: 8
Poster Number: 5313
Title: Combining gene expression and mutation profiling in a single cfDNA assay through the addition of a custom hybrid capture panel targeting gene regulatory regions to a commercial CGP panel
Abstract Number: 7293
Session Title: Liquid Biopsies: Circulating Nucleic Acids 4
Poster Section: 45 | Poster Board: 9
Poster Number: 5314
Title: Fragmentomics analysis of targeted hybrid capture NGS cfDNA gene panel data yields an orthogonal genomic dimension for developing a robust prognostic model for metastatic breast cancer patients
Abstract Number: 3960
Session Title: Prognostic Biomarkers 3
Poster Section: 47 | Poster Board: 10
Poster Number: 5372
The posters will be accessible under the News & Events section of GeneCentric’s website following the conference.
Discovery Life Sciences Flash Talk
Date & Time: Tuesday, April 21, 3:30pm PT
Location: Exhibit Booth 3038
Title: Beyond mutations: rapid cfDNA assay development for quantitative gene expression and tumor phenotyping
Speaker: Jim Davison, PhD, Director, Translational Genomics, GeneCentric
About GeneCentric
GeneCentric is a precision diagnostics company that aims to address the urgent unmet need for better therapeutic biomarkers in solid tumors and bring those biomarkers to comprehensive liquid biopsy testing. With more than a decade of expertise in gene expression, GeneCentric’s ExpressCT™ technology uses fragmentomics to robustly infer gene expression using information embedded in cfDNA. Applying this technology through GenomicsNext™, its best-in-class enabler of liquid biopsy technologies, discoveries, and applications, GeneCentric helps identify and deliver critical biomarkers that point to potential oncology treatment benefit. GeneCentric provides its technology through strategic collaborations with biopharmaceutical and diagnostics companies in applications throughout preclinical testing, clinical drug development, and commercialization lifecycle phases. For more information, visit www.genecentric.com or follow us on LinkedIn.
CONTACT: MEDIA CONTACT: Robin Fastenau Robin.Fastenau@GeneCentric.com
